Features of the Gut Microbiota in Patients with Polycystic Ovary Syndrome

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. Polycystic ovary syndrome (PCOS) is the most common endocrinopathy associated with infertility and metabolic disorders. The ethology and pathogenesis of PCOS are not fully understood. The role of gut microbiota (GM) disorders in the genesis of insulin resistance and in the development of PCOS is ambiguous.

Aims — to compare the GM of patients with PCOS and healthy women, to evaluate the relationship of various groups of microorganisms with markers of chronic inflammation.

Methods. A single-center cross-sectional study was conducted involving 148 women: 118 with PCOS and 30 somatically healthy women aged 18–40 years. A comprehensive clinical, laboratory and instrumental examination was performed, as well as an assessment of the composition of the GM using the cultural analysis method.

Results. In PCOS, a decrease in the GM diversity Margalef index was revealed compared to healthy women. A statistically significant decrease in the level of colonization of Bacteroides (B. vulgatus, B. eggerthii, B. caccae), Lactobacillus gasseri, Lacticaseibacillus rhamnosus, Escherichia coli (E.coli) and, on the contrary, an increase in the population of gamma-proteobacteria of the family Enterobacteriaceae and beta-proteobacteria of the order Burkholderiales, as well as Erysipelatoclostridium ramosum (E. ramosum), compared with healthy women. Correlation analysis revealed a negative correlation of bacteria of the genera Lactobacillus, Bifidobacterium, Bacteroides with IL-6, as well as E. coli with IL-6 and C-reactive protein in patients with PCOS. A positive correlation was observed between the level of IL-6 and the abundance of bacteria of the species E. ramosum.

Conclusions. The GM of PCOS patients is characterized by a decrease in Margalef diversity index, aggravated by the imbalance in microbial communities, accompanied by an increase in the levels of pro-inflammatory markers, compared with healthy women.

Full Text

Restricted Access

About the authors

Ekaterina D. Kirillova

V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology

Author for correspondence.
Email: emiroshina.md@gmail.com
ORCID iD: 0000-0002-3723-5052

Junior Research Assistant

Russian Federation, 4 Oparina Academician str., 117997, Moscow

Vera V. Muravieva

V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology

Email: ammur14@mail.ru
ORCID iD: 0000-0003-0383-0731
SPIN-code: 5831-3030

PhD in Biology, Senior Researcher

Russian Federation, 4 Oparina Academician str., 117997, Moscow

Elena L. Isaeva

V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology

Email: e_isaeva@oparina4.ru
ORCID iD: 0000-0001-6224-8202

MD, PhD, Senior Researcher]

Russian Federation, 4 Oparina Academician str., 117997, Moscow

Aleksey V. Skorobogatiy

V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology

Email: a_skorobogatiy@oparina4.ru
ORCID iD: 0000-0003-2137-6421

Junior Research Assistant

Russian Federation, 4 Oparina Academician str., 117997, Moscow

Ksenya N. Zhigalova

V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology

Email: k_zhigalova@oparina4.ru
ORCID iD: 0000-0001-6949-5759
SPIN-code: 3899-2245

Junior Research Assistant]

Russian Federation, 4 Oparina Academician str., 117997, Moscow

Anastasia A. Kozlova

V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology

Email: aakozlova.box@gmail.com
ORCID iD: 0000-0002-9911-5929

PhD, Student

Russian Federation, 4 Oparina Academician str., 117997, Moscow

Tatiana V. Priputnevich

V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology

Email: priput1@gmail.com
ORCID iD: 0000-0002-4126-9730
SPIN-code: 8383-7023

MD, PhD, Corresponding Member of the RAS

Russian Federation, 4 Oparina Academician str., 117997, Moscow

Galina E. Chernukha

V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology

Email: c-galina1@yandex.ru
ORCID iD: 0000-0002-9065-5689
SPIN-code: 5514-3483

MD, PhD, Professor

4 Oparina Academician str., 117997, Moscow

References

  1. Deswal R, Narwal V, Dang A, et al. The Prevalence of polycystic ovary syndrome: a brief systematic review. J Hum Reprod Sci. 2020;13(4):261–271. doi: https://doi.org/10.4103/jhrs.JHRS_95_18
  2. Kelly CC, Lyall H, Petrie JR, et al. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 2001;86(6):2453–2455. doi: https://doi.org/10.1210/jcem.86.6.7580
  3. Flint HJ. Obesity and the gut microbiota. J Clin Gastroenterol. 2011;45 Suppl:S128–S132. doi: https://doi.org/10.1097/MCG.0b013e31821f44c4
  4. Esteve E, Ricart W, Fernández-Real JM. Gut microbiota interactions with obesity, insulin resistance and type 2 diabetes: did gut microbiote co-evolve with insulin resistance? Curr Opin Clin Nutr Metab Care. 2011;14(5):483–490. doi: https://doi.org/10.1097/MCO.0b013e328348c06d
  5. Tremaroli V, Bäckhed F. Functional interactions between the gut microbiota and host metabolism. Nature. 2012;489(7415):242–249. doi: https://doi.org/10.1038/nature11552
  6. Zhao X, Jiang Y, Xi H, et al. Exploration of the relationship between gut microbiota and polycystic ovary syndrome (PCOS): a Review. Geburtshilfe Frauenheilkd. 2020;80(2):161–171. doi: https://doi.org/10.1055/a-1081-2036
  7. Tremellen K, Pearce K. Dysbiosis of Gut Microbiota (DOGMA)-a novel theory for the development of polycystic ovarian syndrome. Med Hypotheses. 2012;79(1):104–112. doi: https://doi.org/10.1016/j.mehy.2012.04.016
  8. Larsen N, Vogensen FK, van den Berg FW, et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One. 2010;5(2):e9085. doi: https://doi.org/10.1371/journal.pone.0009085
  9. Guo Y, Qi Y, Yang X, et al. Association between polycystic ovary syndrome and gut microbiota. PLoS One. 2016;11(4):e0153196. doi: https://doi.org/10.1371/journal.pone.0153196
  10. Kelley ST, Skarra DV, Rivera AJ, et al. The gut microbiome is altered in a letrozole-induced mouse model of polycystic ovary syndrome. PLoS One. 2016;11(1):e0146509. doi: https://doi.org/10.1371/journal.pone.0146509
  11. Kauffman AS, Thackray VG, Ryan GE, et al. A novel letrozole model recapitulates both the reproductive and metabolic phenotypes of polycystic ovary syndrome in female mice. Biol Reprod. 2015;93(3):69. doi: https://doi.org/10.1095/biolreprod.115.131631
  12. Mukherjee AG, Wanjari UR, Kannampuzha S, et al. The implication of mechanistic approaches and the role of the microbiome in polycystic ovary syndrome (PCOS): A review. Metabolites. 2023;13(1):129. doi: https://doi.org/10.3390/metabo13010129
  13. Адамян Л.В., Андреева Е.Н., Абсатарова Ю.С., и др. Клинические рекомендации «Синдром поликистозных яичников» // Проблемы эндокринологии. — 2022. — Т. 68. — № 2. — С. 112–127. [Adamyan LV, Andreeva EN, Absatarova YuS, et al. Klinicheskie rekomendacii “Sindrom polikistoznyh yaichnikov” // Problemy endokrinologii. 2022;68(2):112–127 (In Russ.)]. doi: https://doi.org/10.14341/probl12874
  14. Бондаренко В.М., Лиходед В.Г. Микробиологическая диагностика дисбактериоза кишечника. Методические рекомендации. — М., 2007. [Bondarenko VM, Lichoded VG. Mikrobiologicheskaya diagnostika disbakterioza kishechnika. Metodicheskiye rekomendatsii. Moscow; 2007 (In Russ.)].
  15. Torres PJ, Siakowska M, Banaszewska B, et al. Gut microbial diversity in women with polycystic ovary syndrome correlates with hyperandrogenism. J Clin Endocrinol Metab. 2018;103(4):1502–1511. doi: https://doi.org/10.1210/jc.2017-02153
  16. Bäckhed F, Ley RE, Sonnenburg JL, et al. Host-bacterial mutualism in the human intestine. Science. 2005;307(5717):1915–1920. doi: https://doi.org/10.1126/science.1104816
  17. Копчак Д.В., Оришак Е.А., Закревский В.В., и др. Возможности использования индивидуально подобранных пробиотиков в лечении пациентов с метаболическим синдромом и дисбактериозом кишечника. // Экспериментальная и клиническая гастроэнтерология. — 2016. — Т. 12. — № 136. — С. 55–59. [Kopchak DV, Orichak EA, Zakrevskii VV, et al. The possibility of using individually selected probiotics in the treatment of patients with metabolic syndrome and intestinal dysbiosis. Experimental and Clinical Gastroenterology. 2016;(12):55–59. (In Russ.)]
  18. Walsh CJ, Guinane CM, O'Toole PW, et al. Beneficial modulation of the gut microbiota. FEBS Lett. 2014;588(22):4120–4130. doi: https://doi.org/10.1016/j.febslet.2014.03.035
  19. Torres PJ, Ho BS, Arroyo P, et al. Exposure to a healthy gut microbiome protects against reproductive and metabolic dysregulation in a PCOS mouse model. Endocrinology. 2019;160(5):1193–1204. doi: https://doi.org/10.1210/en.2019-00050
  20. Qi X, Yun C, Sun L, et al. Gut microbiota-bile acid-interleukin-22 axis orchestrates polycystic ovary syndrome. Nat Med. 2019;25(8):1225-1233. doi: https://doi.org/10.1038/s41591-019-0509-0
  21. Яковлева М.В., Червинец В.М., Червинец Ю.В., и др. Микробиота кишечника и полости рта у больных артериальной гипертензией с метаболическим синдромом // Патологическая физиология и экспериментальная терапия. — 2020. — Т. 64. — № 4. — С. 101–105. [Yakovleva M, Chervinets V, Chervinets Y, et al. Gut and oral microbiota in patients with arterial hypertension and metabolic syndrome. Patologicheskaya Fiziologiya i Eksperimental’naya Terapiya (Pathological physiology and experimental therapy). 2020;64(4):101–105. (In Russ.)]
  22. Kim S, Covington A, EG P. The intestinal microbiota: antibiotics, colonization resistance, and enteric pathogens. Immunol Rev. 2017;279(1):90–105. doi: https://doi.org/10.1111 /imr.12563
  23. Wexler HM. Bacteroides: the good, the bad, and the nitty-gritty. Clin Microbiol Rev. 2007;20(4):593–621. doi: https://doi.org/10.1128/CMR.00008-07
  24. Shimizu J, Kubota T, Takada E, et al. Propionate-producing bacteria in the intestine may associate with skewed responses of IL10-producing regulatory T cells in patients with relapsing polychondritis. PLoS One. 2018;13(9):e0203657. doi: https://doi.org/10.1371/journal.pone.0203657
  25. You HJ, Si J, Kim J, et al. Bacteroides vulgatus SNUG 40005 restores akkermansia depletion by metabolite modulation. Gastroenterology. 2023;164(1):103–116. doi: https://doi.org/10.1053/j.gastro.2022.09.040
  26. Guo S, Nighot M, Al-Sadi R, et al. Lipopolysaccharide regulation of intestinal tight junction permeability is mediated by TLR4 signal transduction pathway activation of FAK and MyD88. J Immunol. 2015;195(10):4999–5010. doi: https://doi.org/10.4049/jimmunol.1402598
  27. Garibotto G, Carta A, Picciotto D, et al. Toll-like receptor-4 signaling mediates inflammation and tissue injury in diabetic nephropathy. J Nephrol. 2017;30(6):719–727. doi: https://doi.org/10.1007/s40620-017-0432-8
  28. Cox AJ, Zhang P, Bowden DW, et al. Increased intestinal permeability as a risk factor for type 2 diabetes. Diabetes Metab. 2017;43(2):163–166. doi: https://doi.org/10.1016/j.diabet.2016.09.004
  29. Laugerette F, Alligier M, Bastard JP, et al. Overfeeding increases postprandial endotoxemia in men: Inflammatory outcome may depend on LPS transporters LBP and sCD14. Mol Nutr Food Res. 2014;58(7):1513–1518. doi: https://doi.org/10.1002/mnfr.201400044
  30. Young RL, Lumsden AL, Martin AM, et al. Augmented capacity for peripheral serotonin release in human obesity. Int J Obes (Lond). 2018;42(11):1880–1889. doi: https://doi.org/10.1038/s41366-018-0047-8
  31. Mandić AD, Woting, A, Jaenicke T et al. Clostridium ramosum regulates enterochromaffin cell development and serotonin release. Sci Rep. 2019;9(1):1177. doi: https://doi.org/10.1038/s41598-018-38018-z
  32. Gurung M, Li Zh, You H, et al. Role of gut microbiota in type 2 diabetes pathophysiology. EBioMed. 2020;51:102590. doi: https://doi.org/10.1016/j.ebiom.2019.11.051
  33. Lee HY, Park JH, Seok SH et al. Human originated bacteria, Lactobacillus rhamnosus PL60, produce conjugated linoleic acid and show anti-obesity effects in diet-induced obese mice. Biochim Biophys Acta. 2006;1761(7):736–744. doi: https://doi.org/10.1590/s0004-2730200900020000
  34. Lee SJ, Bose S, Seo JG, et al. The effects of co-administration of probiotics with herbal medicine on obesity, metabolic endotoxemia and dysbiosis: A randomized double-blind controlled clinical trial. Clin Nutr. 2014;33(6)973–981. doi: https://doi.org/10.1016/j.clnu.2013.12.00
  35. Cho YA, Kim J. Effect of probiotics on blood lipid concentrations: a meta-analysis of randomized controlled trials. Medicine (Baltimore). 2015;94(43):1714. doi: https://doi.org/10.1097/MD.0000000000001714
  36. Mahboobi S, Iraj B, Maghsoudi Z, et al. The effects of probiotic supplementation on markers of blood lipids, and blood pressure in patients with prediabetes: a randomized clinical trial. Int J Prev Med. 2014;5(10):1239–1246.
  37. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;116(7):1793–1801. doi: https://doi.org/10.1172/JCI29069

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Fig.1. Study participant selection flowchart

Download (273KB)
3. Fig.2. Composition of the intestinal microbiota in women with polycystic ovary syndrome

Download (345KB)
4. Fig.3. Composition of the intestinal microbiota in healthy women

Download (266KB)
5. Fig.4. Species richness of the intestinal microbiota in patients with polycystic ovary syndrome and in the comparison group (Margalef index)

Download (100KB)
6. Fig.5. Frequency of occurrence of the main groups of microorganisms in patients with polycystic ovary syndrome and in the comparison group

Download (205KB)
7. Fig.6. Heat map of the composition of the intestinal microbiota of patients with polycystic ovary syndrome and healthy women

Download (716KB)
8. Fig.7. Results of correlation analysis of the quantitative composition of intestinal microbiota and markers of chronic inflammation

Download (241KB)

Copyright (c) 2023 "Paediatrician" Publishers LLC



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies